Campbell, Jonathan E
Ussher, John R
Mulvihill, Erin E
Kolic, Jelena
Baggio, Laurie L
Cao, Xiemen
Liu, Yu
Lamont, Benjamin J
Morii, Tsukasa
Streutker, Catherine J
Tamarina, Natalia
Philipson, Louis H
Wrana, Jeffrey L
MacDonald, Patrick E
Drucker, Daniel J
Article History
Received: 24 August 2015
Accepted: 26 October 2015
First Online: 7 December 2015
Competing interests
: D.J.D. has been a consultant to Novo Nordisk Inc. and other companies that develop and/or sell incretin-based therapies, including Arisaph Pharmaceuticals Inc., Intarcia Therapeutics, Merck Research Laboratories, MedImmune, Receptos, Sanofi, Takeda and Transition Pharmaceuticals Inc. Neither D.J.D. nor his family members hold stock directly or indirectly in any of these companies.